Rodríguez-Covarrubias F, Castillejos-Molina RA, Sotomayor de Zavaleta M, Feria-Bernal G

Language: Spanish
References: 20
Page: 220-224
PDF size: 142.51 Kb.

ABSTRACT

Objective: To become familiar with the results of Radical Retropubic Prostatectomy (RRP) as a treatment method in clinically localized prostate cancer (PCa).
Materials and methods: Patients presenting with clinically localized PCa, surgically treated in our Institute, were divided into risk groups according to the D’Amico classification and their progress was analyzed. Biochemical recurrence-free survival was evaluated by the Kaplan-Meier method. Factors associated with biochemical recurrence were analyzed by uni-and multivariate analyses.
Results: A total of 205 clinically localized PCa patients underwent RRP. Mean prostate specific antigen (PSA) was 13.78+13.34 ng/ml. Pathology stage distribution was 131 (64%) stage pT2 patients, 31 (15%) stage pT3a patients and 12 (6%) patients presenting with lymph node invasion (N+). The sum of definitive Gleason scores was ‹6, 7 and ›8 in 97 (47%), 75 (37%) and 33 (16%) cases, respectively. Mean follow-up time was 41+30 months. Recurrencefree survival at 10 years in those patients presenting with PS4 ‹10, from 10-20 and ›20 ng/ml was 69%, 45% and 11%, respectively (P‹0.0001). For patients in the low-, intermediate- and high-risk groups, recurrence-free survival was 76%, 51% and 17%, respectively (P‹0.0001). The factors associated with biochemical recurrence by multivariate analysis were a PSA ›10 ng/ml (P=0.004) and the pathology stage (P=0.01).
Conclusions: Patients diagnosed with clinically localized PCa who presented with low PSA, early pathology stage and were in the low-risk group had a better survival rate after RRP. According to our results, these factors predict the possibility of biochemical relapse after surgical treatment.

REFERENCES

1. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9.

2. Mitchell RE, Desai M, Shah JB, Olsson CA, Benson MC, McKiernan JM. Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J Urol 2006;175(5):1663-7.

3. Swanson GP, Riggs MW, Earle JD, Haddock MG. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol 2002;42(3):212-6.

4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-23.

5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7.

6. Rodríguez-Covarrubias F, Castillejos-Molina R, Sotomayor de Zavaleta M et al. Biochemical failure according to the risk group in patients with prostate adenocarcinoma. Presentado en 84th Annual South Central Section Meeting, South Central Section of the AUA Austin, Texas, EUA. Septiembre 2005.

7. Swindle P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005;174(3):903-7.

8. D’Amico AV, Whittington R, Malkowicz SB et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166(6):2185-8.

9. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74.

10. Greene FL, Page DL, Fleaming ID et al. American Joint Committee on Cancer, Manual for staging cancer (ed 6). New York, NY, Springer 2002:337-346.

11. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998;160(6 Pt 2):2418-24.

12. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165(4):1146-51.

13. Rodríguez-Covarrubias F, Castillejos-Molina R, Sotomayor de Zavaleta M et al. Recurrencia bioquímica según el grupo de riesgo en pacientes con adenocarcinoma de próstata. Rev Mex Urol 2004;64(1):6-12.

14. Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ. Preoperative PSA level is significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology 2004;64(4):723-8.

15. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169(1):157-63.

16. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002;59(5):740-5.

17. Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int 2006;97(1):51-5.

18. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23(22):4975-9.

19. Bolla M, van Poppel H, Collete L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366:572-578.